EGFR is overexpressed in glioblastoma, breast, and lung cancers leading to dysregulation of the EGFR pathway and increased cell proliferation (Sigismund et al., 2018; Talukdar et al., 2020; Uribe et al., 2021). Here, EGFR is linked to lung carcinoma.